Cargando…
The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence
The current strategy of searching for an effective treatment for COVID-19 relies mainly on repurposing existing therapies developed to target other diseases. Conflicting results have emerged in regard to the efficacy of several tested compounds but later results were negative. The number of conducte...
Autores principales: | Maziarz, Mariusz, Stencel, Adrian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579070/ https://www.ncbi.nlm.nih.gov/pubmed/36258007 http://dx.doi.org/10.1007/s40656-022-00532-9 |
Ejemplares similares
-
Clinical features and mechanistic insights into drug repurposing for combating COVID-19
por: Asrani, Purva, et al.
Publicado: (2022) -
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
por: Regan, Kelly, et al.
Publicado: (2016) -
Mechanistic action of weak acid drugs on biofilms
por: Kundukad, Binu, et al.
Publicado: (2017) -
Drug Repurposing for COVID-19 using Graph Neural Network with Genetic, Mechanistic, and Epidemiological Validation
por: Hsieh, Kanglin, et al.
Publicado: (2020) -
Inference of differential key regulatory networks and mechanistic drug repurposing candidates from scRNA-seq data with SCANet
por: Oubounyt, Mhaned, et al.
Publicado: (2023)